Claims
- 1. A method for determining pancreatic exocrine function in a patient's body comprising the patient ingesting an ester R2COOR1 where R1 is a sterol group, and R2 is a traceable hydrocarbon group oxidizable to traceable carbon dioxide in the body, said traceable carbon dioxide being expired from the body in the breath, and detecting the rate of appearance of said traceable carbon dioxide in the breath of said patient and comparing the rate of appearance of said traceable carbon dioxide produced when said ester is ingested alone with the rate of traceable carbon dioxide produced when said ester is ingested with exogenously added pancreatic enzymes suitable for hydrolyzing said ester as an indication of pancreatic exocrine function.
- 2. A method according to claim 1 wherein said R2 traceable hydrocarbon group comprises from 2 to 10 carbon atoms.
- 3. A method according to claim 2 wherein said traceable R2 hydrocarbon group comprises one or more carbon atoms of either .sup.14 C or .sup.13 C.
- 4. A method according to claim 3 wherein the ester is prepared for patient injestion by combining said ester with a triglyceride in solution and agitating said solution forming a lipid matrix of triglyceride situated about said ester and suspending said lipid matrix in an aqueous solution.
- 5. A method for determing pancreatic exocrine function in a patient's body comprising the patient ingesting simultaneously an ester R2COOR1, and a salt of a fatty acid R3COOH, wherein R1 is a sterol group, and R2 and R3 are differentially traceable groups oxidizable to differentially traceable carbon dioxides in the body, said differentially traceable carbon dioxides being expired from said body in the breath and detecting said differentially traceable carbon dioxides in the breath of said patient, and comparing the rates of appearance of said differentially traceable carbon dioxides as an indication of pancreatic exocrine function.
- 6. A method according to claim 5 wherein said R2 group comprises from 2 to 10 carbon atoms and one or more of said carbon atoms is .sup.14 C or .sup.13 C.
- 7. A method according to claim 6 wherein R3 comprises from 2 to 10 carbon atoms and one or more of said carbon atoms is labelled with .sup.14 C or.sup.13 C.
- 8. A method according to claim 7 wherein R1 is cholesterol.
- 9. A method according to claim 8 wherein said ester is cholesterol octanoate.
- 10. A method according to claim 9 wherein said salt of said fatty acid is an octanoate salt.
- 11. A method according to claim 8 wherein said ester, and said salt of said fatty acid are prepared for patient ingestion by combining said ester and said fatty acid salt with a triglyceride in solution, and agitating said solution thereby forming a lipid matrix of said triglyceride situated about said ester and fatty acid salt and suspending said lipid matrix in an aqueous solution.
- 12. A composition useful for determining pancreatic exocrine function prepared by combining in aqueous solution a triglyceride, cholesterol octanoate, and an octanoate salt, and agitating said solution to form a lipid matrix, said lipid matrix comprising said triglyceride, cholesterol octanoate, and octanoate salt, and said cholesterol octanoate and octanoate salt exhibiting one or more different traceable isotopes of carbon detectable as carbon dioxide.
ACKNOWLEDGEMENT
This invention was made with Government support under Grant No. AM 21506 awarded by the National Institute of Health, Department of Health and Human Services. The Government has certain rights in this invention.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3844894 |
Kronick et al. |
Oct 1974 |
|
3917812 |
Woog et al. |
Nov 1975 |
|
Non-Patent Literature Citations (1)
Entry |
Blomstrand et al., "Acta Chir. Scand.", 134:667-669 (1968). |